The stock may react positively to the strong 2026 guidance despite weak current results, particularly the significant reduction in Medicare Cap headwinds. Monitor VITAS admissions growth and Roto-Rooter margin recovery as key indicators of execution. The company's share repurchase activity ($174.6M in the quarter) provides additional support.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $396.63entry
- T+1 · 9mo ago +3.37%α +3.83% · $410.01
- T+5 · 9mo ago +3.92%α +5.04% · $412.16
- T+20 · 8mo ago −6.22%α +0.18% · $371.95
- T+60 · 6mo ago +11.33%α +3.57% · $441.55
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Chemed Corp reported flat Q4 2025 revenue of $639.3 million but a 9% decline in GAAP EPS to $5.48. The VITAS segment showed modest growth in net patient revenue (1.9%) and admissions (6%), while Roto-Rooter revenue declined 3.7%. The company provided strong 2026 guidance with EPS expected to grow to $23.25-$24.25, driven by a significant reduction in Medicare Cap billing limitations and projected revenue growth across both segments.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $639.3 million, essentially flat YoY
- GAAP EPS was $5.48, down 9% YoY; Adjusted EPS was $6.42, down 6% YoY
- VITAS net patient revenue increased 1.9% to $418.8 million with 6% growth in admissions
- Roto-Rooter revenue decreased 3.7% to $220.6 million with significant margin compression
- 2026 guidance projects EPS of $23.25-$24.25 (up from $21.55 in 2025) with VITAS revenue growth of 5.5%-6.5% and Roto-Rooter growth of 3.0%-3.5%
- Medicare Cap billing limitations expected to decrease to $9.5 million in 2026 from $27.2 million in 2025
Financial Impact
Revenue flat at $639.3M, EPS down 9% to $5.48, but 2026 guidance shows significant improvement with EPS expected to grow to $23.25-$24.25
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| VITAS | $418.8M | +1.9% |
| Roto-Rooter | $220.6M | -3.7% |
Risk Factors
- Roto-Rooter segment showing declining revenue and significant margin pressure
- Execution risk on the optimistic 2026 guidance, particularly the margin improvement targets
- Concentration risk in VITAS segment's Medicare reimbursement policies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000019584-26-000002 |
| Document: che-20260225x8k.htm | 0000019584-26-000002 |
| Document: 0000019584-26-000002-index-headers.html | 0000019584-26-000002 |
| Document: 0000019584-26-000002-index.html | 0000019584-26-000002 |
| Document: 0000019584-26-000002.txt | 0000019584-26-000002 |
Track record
19 reports on CHE
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +2.86% at T+5 after the Oct 27, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $528.05 to $548.20 Now $549.45 +4.05% ▲ +3.82% +1.22% vs SPY
- Nov 5, 202611d ago Insider Cluster Bearish 4/10 Entry $533.77 to $550.20 Now $549.45 −2.94% ▼ −3.08% +0.21% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $533.65 to $544.49 Now $549.45 +2.96% ▲ +2.03% +2.62% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $533.36 to $548.64 Now $549.45 +3.02% ▲ +2.86% +3.58% vs SPY
- Oct 27, 202620d ago 8-K Bullish 6/10 No price data
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $533.36 to $548.64 Now $549.45 +3.02% ▲ +2.86% +3.58% vs SPY
- Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $512.98 to $534.72 Now $549.45 +7.11% ▲ +4.24% +4.80% vs SPY
- Oct 1, 20266w ago Press Release Neutral 1/10 Entry $502.90 to $498.25 Now $549.45 +9.26% ▼ −0.92% −2.23% vs SPY
- Sep 16, 20268w ago Press Release Neutral 4/10 Entry $505.97 to $495.65 Now $549.45 +8.59% ▼ −2.04% −2.64% vs SPY
- Aug 24, 202612w ago Insider Cluster Neutral 3/10 Entry $541.34 to $518.71 Now $549.45 +1.50% ▼ −4.18% −4.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers